methylnaltrexone bromide
Enable an AI agent to recognise methylnaltrexone bromide, assess a material lot's identity and fitness, and determine which handling or downstream-use decisions require further evidence.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 18 findings · 30 questions
Salt and stereochemical identity Establish exactly which methylnaltrexone species the entry and a physical sample represent.
Cation structure
Resolve molecular connectivity and stereochemical identity.
Reference structure match
Require structural evidence that can distinguish the intended substance from naltrexone and stereochemical alternatives.
- Which authenticated structure and stereochemical identifier define the registered methylnaltrexone bromide? definition
- Which analytical comparison distinguishes the intended stereochemistry from possible stereoisomer impurities? measurement
Bromide and identifiers
Resolve counterion composition and external identity mappings.
Salt record resolution
Map identifiers to the complete salt and document any differences in stereochemical or hydration specificity.
- What measurements confirm bromide identity and its molar ratio to the methylnaltrexone cation? measurement
- Which CAS, PubChem, EC or other authority records refer to this exact salt rather than the cation or a stereoisomer? provenance
Assay and lot quality Determine how much qualifying methylnaltrexone bromide a lot contains.
Content basis
Reconcile salt content, cation equivalents and moisture corrections.
Comparable content
Keep salt mass and cation-equivalent mass explicit; the product label distinguishes these quantities. [RELISTOR prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99).
- Does the reported assay quantify methylnaltrexone bromide or methylnaltrexone cation equivalents? definition
- Which water, solvent and reference-standard potency corrections were applied to the result? measurement
Impurities and release
Connect analytical quality to a specified intended use.
Lot fitness evidence
Assess stereoisomers, related substances and residual materials against a traceable lot specification.
- Which tests quantify stereoisomer impurities, related substances, water and residual solvents, and with what reporting limits? measurement
- Which approved specification and certificate of analysis support releasing this lot for its declared use? action
Physical form and stability Record the actual material form and the conditions under which it remains suitable.
Solid and solution properties
Establish form-specific properties relevant to weighing, dissolution and processing.
Conditioned property measurements
Tie solid-form identification, solubility and thermal measurements to sample composition and experimental conditions.
- Is the tested salt crystalline, amorphous, hydrated or solvated, and what measurements establish that state? measurement
- What solubility and thermal-event data apply at specified solvent, pH, temperature and pressure conditions? measurement
- Does a reported thermal endpoint represent melting, solvent loss or decomposition, and is a boiling point meaningful? boundary
Storage and degradation
Connect exposure history and stability data to remaining material fitness.
Supported retest status
Use stability-indicating evidence for the bulk salt or specified solution rather than borrowing finished-product expiry conditions.
- Which stability studies support this material's container, temperature, humidity and light limits? provenance
- After an excursion or prolonged storage, which results determine whether to retest, release or reject the lot? action
Pharmacology and product boundary Connect substance identity to biological action and separately governed medicinal presentations.
Peripheral antagonism
Represent receptor activity with its experimental and physiological limits.
Activity and distribution
Methylnaltrexone is a mu-opioid receptor antagonist whose quaternary structure restricts blood-brain barrier passage; restricted passage should not be modelled as absolute exclusion. [RELISTOR prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99).
- Which receptor assays establish antagonist activity, and do their concentrations use salt or cation units? measurement
- Which evidence defines the limits of peripheral selectivity under altered barrier integrity or exposure? boundary
Ingredient to medicine
Separate an ingredient lot from authorised formulations and therapeutic decisions.
Product linkage
Link methylnaltrexone bromide to a product through ingredient identity, specification and quantity basis.
- Which product record identifies this salt as its active ingredient and specifies the relevant ingredient quality? provenance
- Which route, formulation, indication and dosing decisions must be delegated to the medicinal-product and patient-care models? boundary
Handling and permitted use Establish evidence for handling and using methylnaltrexone bromide in a particular setting.
Occupational and environmental hazards
Resolve hazards for the supplied salt and its actual exposure form.
Applicable hazard evidence
Keep workplace classification, exposure controls and disposal evidence separate from clinical adverse-effect information.
- Which current SDS and jurisdiction-specific classification apply to this methylnaltrexone bromide material? provenance
- What exposure-limit or occupational-band evidence supports controls for weighing powder or handling solutions? action
- Which substance-specific evidence determines spill response and waste disposal requirements? action
Grade and jurisdiction
Determine permitted uses from material qualification and applicable authority records.
Use qualification
Require a documented match between supplier qualification, material grade, intended operation and jurisdiction.
- Which manufacturer, lot and quality-system records substantiate the declared methylnaltrexone bromide grade? provenance
- Which jurisdiction-specific requirements must be satisfied before this lot can enter pharmaceutical manufacture or another proposed use? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these standards and regulation hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of methylnaltrexone bromide this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
What it is Filled
Methylnaltrexone bromide is the bromide salt of methylnaltrexone, a quaternary ammonium derivative of naltrexone that antagonizes peripheral μ-opioid receptors and is used to treat opioid-induced constipation.
In scope
- Methylnaltrexone cation identity, stereochemistry and bromide counterion
- Salt content, assay basis, impurities and material grade
- Solid or dissolved state and condition-dependent physical properties
- Lot provenance, analytical evidence and stability status
- Relationships to opioid receptor antagonism and medicinal products
- Substance-specific handling hazards and jurisdictional identifiers
Out of scope
- Finished RELISTOR tablets, injections, excipients and delivery devices
- Patient-specific prescribing, dosing and treatment monitoring
- Opioid-induced constipation as a disease or treatment pathway
- Manufacturing equipment and synthesis process execution
- Naltrexone, other opioid antagonists and methylnaltrexone metabolites as independent substances
Why it exists Filled
Enable an AI agent to recognise methylnaltrexone bromide, assess a material lot's identity and fitness, and determine which handling or downstream-use decisions require further evidence.
Distinguishing features Filled
- Verify the bromide salt rather than identifying only the methylnaltrexone cation; PubChem distinguishes salt CID 5361917 from cation CID 5361918. [PubChem salt record](https://pubchem.ncbi.nlm.nih.gov/compound/5361917), [PubChem cation record](https://pubchem.ncbi.nlm.nih.gov/compound/Methylnaltrexone).
- Check the quaternary nitrogen and stereochemical structure against an authenticated methylnaltrexone bromide reference; a name containing naltrexone is insufficient. [RELISTOR prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99).
- Check compatibility with formula C21H26BrNO4 and formula mass 436.36 g/mol, while recognising that these alone do not distinguish stereoisomers. [RELISTOR prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c488fb7c-0a5b-487c-b452-996809d1cb99).
- Distinguish an identified bulk substance from a formulated medicine by checking excipients, presentation and lot documentation.
What robots and AI may and may not do Filled
Must not
- Recommend, dose or supply it to a person without a prescriber's decision.
- Advise its use when bowel obstruction is suspected.
- Present it as a treatment for opioid overdose or addiction.
Only with a human decision
- Any decision to start or stop it, especially in palliative care.
May
- Describe methylnaltrexone's action on gut opioid receptors and its use in opioid-induced constipation.
- Explain that it does not block pain relief in the brain under normal use.
Moral aspects Filled
- Many users are in palliative care, where comfort and dignity must guide every decision.
Who is affected
- Patients on opioids
- Palliative care patients
- Carers
Owners Filled
Steward
The marketing authorisation holder; the prescriber answers for each use.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.methylnaltrexone-bromide
- Wikidata: Q59904170 (https://www.wikidata.org/wiki/Q59904170)
Direct properties required Filled
- Stereochemical salt identity: Authenticated structure, stereochemical identifier and bromide counterion
- Assay and reporting basis: % w/w; as received, dried or anhydrous; bromide salt or cation equivalent
- Bromide stoichiometry: mol bromide/mol methylnaltrexone cation
- Related substances and stereoisomer content: % by validated method, with response factors and reporting limits
- Water and residual solvents: Water % w/w; individual solvents ppm or mg/kg
- Material state: Solid or solution; identified solid form; temperature, humidity and solvent context
- Solubility and thermal behaviour: Solubility in mg/mL with solvent, pH and temperature; thermal events in °C with method
- Material grade and disposition: Declared grade; quarantined, released, rejected or awaiting retest against a named specification
- Pharmacological relationship: Methylnaltrexone moiety to peripheral mu-opioid receptor antagonism
- Hazard and regulatory evidence: Applicable SDS, identifier records, jurisdiction, revision date and exposure-limit evidence
Recognition required Filled
- Supplied as an injection or tablets; identity is confirmed by label and pharmacy records.
Capabilities and actions required Filled
- Match a supplier lot to the registered substance using structural, counterion and analytical evidence.
- Compare assay results after reconciling salt, cation and water-content bases.
- Assess a lot against a specified research or pharmaceutical material specification.
- Evaluate proposed dissolution and storage conditions using evidence for the actual material form.
- Link a qualifying ingredient lot to a separately modelled medicinal product.
- Flag missing hazard, stability or identity evidence before release or use.
Hazards and failure modes required Filled
- Bowel perforation in patients with gut lesions or obstruction.
- Abdominal pain and diarrhoea.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology places methylnaltrexone bromide under A06AH01, within peripheral opioid receptor antagonists.
Context of use required Filled
- Methylnaltrexone bromide is encountered in pharmaceutical manufacture, analytical testing and research on peripheral opioid receptor antagonism.
- It is used as an active pharmaceutical ingredient in medicines for opioid-induced constipation, with suitability depending on documented identity, purity and the intended product.
Sources Filled
- Wikidata item Q59904170: methylnaltrexone bromide - identity and sense of the item
- Wikipedia: Methylnaltrexone - general description of the item
Open questions
- Which authoritative CAS and EC mappings unambiguously resolve the intended stereochemistry and distinguish the bromide salt from less-specific records?
- Which solid forms, hydration states, solubility measurements and thermal endpoints are supported by primary measurements for the relevant grade?
- Which current compendial or approved specifications define assay, stereoisomer, related-substance and residual-solvent limits?
- What bulk-material stability evidence establishes packaging, storage conditions and retest periods independently of finished medicines?
- Which current SDS classifications, occupational exposure limits or bands, and environmental disposal requirements apply in the intended jurisdiction?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q59904170/spec.json